The FDA recently issued a warning letter to India-based generic drug company, Cadila Healthcare, for failing to meet the regulatory standards of the U.S., reported Chemical & Engineering News.
Although the FDA has not made the letter public yet, the report said that the company told the Bombay Stock Exchange, in a statement, that the letter covered, "two plants, one making active pharmaceutical ingredients and the other formulations."
It was not immediately clear what the violations were.
